Pila Pharma

Pila Pharma EBIT Margin

The EBIT Margin (Operating Margin) of Pila Pharma (PILA.ST) as of Oct 28, 2026 is -700.44 %. In the previous year, EBIT Margin (Operating Margin) was -1,046.32 % — a change of -33.06% (higher).

EBIT Margin

-700.44 %

YoY

-33.06%

Last updated:

EBIT Margin (Operating Margin) of Pila Pharma is 2025 -700.44 % . EBIT Margin (Operating Margin) of Pila Pharma was 2024 -1,046.32 % . It decreases by -33.06% higher compared to the previous year.

Pila Pharma's operating (EBIT) margin stands at -700.4%, up from -1,287.6% several years earlier.

The Pila Pharma EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2019
-2,502.09 SEK
Jan 1, 2021
-1,287.57 SEK
Jan 1, 2022
-472.69 SEK
Jan 1, 2023
-436.99 SEK
Jan 1, 2024
-1,046.32 SEK
Jan 1, 2025
-700.44 SEK
The Pila Pharma EBIT Margin history
YEAREBIT MarginYoY
-700.44 %-33.06%
-1,046.32 %+139.44%
-436.99 %-7.55%
-472.69 %-63.29%
-1,287.57 %-48.54%
-2,502.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pila Pharma Stock analysis

What does Pila Pharma do? Pila Pharma AB develops pharmaceutical products, focusing on XEN-D0501, a TRPV1 antagonist for type 2 diabetes treatment. The company conducts phase 2 clinical trials, including PP-CT01 and PP-CT02, which confirmed XEN-D0501's tolerability and potential for fewer side effects compared to existing treatments. Pila Pharma AB generates revenue through research and development of its patent-protected product candidate, targeting early-stage diabetes patients requiring oral medication to restore insulin production and lower blood sugar levels. The firm's primary product, XEN-D0501, is an orally administered tablet designed for early diabetes management. Clinical trials have shown positive results, supporting the product's safety profile and efficacy. Pila Pharma AB's business model centers on advancing its proprietary drug candidate through clinical development to secure regulatory approval and commercialization in the pharmaceutical market. Pila Pharma AB targets healthcare providers and patients with type 2 diabetes seeking innovative treatment options. The company's focus on phase 2 clinical trials positions it to address unmet medical needs in diabetes care, leveraging its patent-protected technology to differentiate XEN-D0501 from competitors. The firm's revenue stream depends on successful clinical outcomes leading to market entry of XEN-D0501. Pila Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pila Pharma stock

EBIT Margin (Operating Margin) of Pila Pharma is -700.44 % in 2025.

EBIT Margin (Operating Margin) of Pila Pharma changed from -1,046.32 % to -700.44 %, representing a -33.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Pila Pharma since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Pila Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Pila Pharma

All Key Metrics — Pila Pharma